Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1444070 | 1.00 | AOC3 (1.00) | AOC3ALDH1A1KDM4EMAPTCYP1A2 | |
| SCHEMBL16735539 | 1.00 | AOC3 (1.00) | AOC3ALDH1A1KDM4EMAPTCYP1A2 | |
| SCHEMBL2210503 | 0.88 | AOC3 (1.00) | AOC3ALDH1A1KDM4EMAPTCYP1A2 | |
| SCHEMBL16735525 | 0.88 | AOC3 (1.00) | AOC3ALDH1A1KDM4EMAPTCYP1A2 | |
| SCHEMBL2210507 | 0.88 | AOC3 (1.00) | AOC3ALDH1A1KDM4EMAPTCYP1A2 | |
| SCHEMBL2187267 | 0.83 | AOC3 (0.71) | AOC3ALDH1A1KDM4EMAPTCYP1A2 | |
| SCHEMBL2187263 | 0.83 | AOC3 (0.71) | AOC3ALDH1A1KDM4EMAPTCYP1A2 | |
| SCHEMBL2189408 | 0.82 | AOC3 (1.00) | AOC3ALDH1A1KDM4EMAPTCYP1A2 | |
| SCHEMBL16735541 | 0.82 | AOC3 (1.00) | AOC3ALDH1A1KDM4EMAPTCYP1A2 | |
| SCHEMBL2189412 | 0.82 | AOC3 (1.00) | AOC3ALDH1A1KDM4EMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131539-B1 | SEMICARBAZIDE-SENSITIVE AMINE OXIDASE INHIBITORS FOR USE AS ANALGESICS IN TRAUMATIC NEUROPATHY AND NEUROGENIC INFLAMMATION | PECSI TUDOMANYEGYETEM (HU) | 2018-12-05 | — | — | EP | claimed |
| US-9790193-B2 | Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation | PÉCSI TUDOMÁNYEGYETEM (HU) | 2017-10-17 | — | — | US | claimed |
| EP-3131539-A1 | SEMICARBAZIDE-SENSITIVE AMINE OXIDASE INHIBITORS FOR USE AS ANALGESICS IN TRAUMATIC NEUROPATHY AND NEUROGENIC INFLAMMATION | Pécsi Tudományegyetem (HU) | 2017-02-22 | — | — | EP | claimed |
| US-20170044117-A1 | SEMICARBAZIDE-SENSITIVE AMINE OXIDASE INHIBITORS FOR USE AS ANALGESICS IN TRAUMATIC NEUROPATHY AND NEUROGENIC INFLAMMATION | PÉCSI TUDOMÁNYEGYETEM (HU) | 2017-02-16 | — | — | US | claimed |
| WO-2015159112-A1 | SEMICARBAZIDE-SENSITIVE AMINE OXIDASE INHIBITORS FOR USE AS ANALGESICS IN TRAUMATIC NEUROPATHY AND NEUROGENIC INFLAMMATION | PÉCSI TUDOMÁNYEGYETEM (HU) | 2015-10-22 | — | — | WO | claimed |
| EP-2342179-B1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2015-05-27 | — | — | EP | claimed |
| US-20110263567-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2011-10-27 | — | — | US | claimed |
| EP-2342179-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | Semmelweis Egyetem (HU) | 2011-07-13 | — | — | EP | claimed |
| WO-2010029379-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2010-03-18 | — | — | WO | claimed |
| US-10576148-B2 | Use of VAP-1 inhibitors for treating fibrotic conditions | BIOTIE THERAPIES CORP. (FI) | 2020-03-03 | — | — | US | disclosed |
| EP-3131539-B1 | SEMICARBAZIDE-SENSITIVE AMINE OXIDASE INHIBITORS FOR USE AS ANALGESICS IN TRAUMATIC NEUROPATHY AND NEUROGENIC INFLAMMATION | PECSI TUDOMANYEGYETEM (HU) | 2018-12-05 | — | — | EP | disclosed |
| US-20180071388-A1 | USE OF VAP-1 INHIBITORS FOR TREATING FIBROTIC CONDITIONS | BIOTIE THERAPIES CORP. (FI) | 2018-03-15 | — | — | US | disclosed |
| EP-2475387-B1 | VAP-1 INHIBITORS FOR USE IN TREATING FIBROTIC CONDITIONS | BIOTIE THERAPIES CORP (FI) | 2017-11-01 | — | — | EP | disclosed |
| US-9795671-B2 | Use of VAP-1 inhibitors for treating fibrotic conditions | BIOTIE THERAPIES CORP. (FI) | 2017-10-24 | — | — | US | disclosed |
| EP-2342179-B1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2015-05-27 | — | — | EP | disclosed |
| US-8536210-B2 | Compounds for inhibiting semicarbazide-sensitive amine oxidase (SSAO)/vascular adhesion protein-1 (VAP-1) and uses thereof for treatment and prevention of diseases | SEMMELWEIS EGYETEM (HU) | 2013-09-17 | — | — | US | disclosed |
| US-20130195883-A1 | USE OF VAP-1 INHIBITORS FOR TREATING FIBROTIC CONDITIONS | THE UNIVERSITY OF BIRMINGHAM (GB) | 2013-08-01 | — | — | US | disclosed |
| EP-2475387-A1 | USE OF VAP-1 INHIBITORS FOR TREATING FIBROTIC CONDITIONS | Biotie Therapies Corp. (FI) | 2012-07-18 | — | — | EP | disclosed |
| US-20110263567-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2011-10-27 | — | — | US | disclosed |
| WO-2011029996-A1 | USE OF VAP-1 INHIBITORS FOR TREATING FIBROTIC CONDITIONS | BIOTIE THERAPIES CORP. (FI) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263567-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | VCAM1, AOX1, AOC3 | AOC3 3/4885ALDH1A1 44/4885KDM4E 2019/4885 |
| US-20170044117-A1 | SEMICARBAZIDE-SENSITIVE AMINE OXIDASE INHIBITORS FOR USE AS ANALGESICS IN TRAUMATIC NEUROPATHY AND NEUROGENIC INFLAMMATION | AOC3, VAPB, AOC2 | AOC3 1/4885ALDH1A1 70/4885KDM4E 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.